(Q34989438)

5 August 2017

1 reference

title

Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence (English)

1 reference

5 August 2017

R Preston Mason

1

1 reference

5 August 2017

language of work or name

1 reference

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

165

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

191-199

1 reference

Molecular bases of the acute coronary syndromes

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Atherosclerosis, calcium, and calcium antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Matrix metalloproteinases and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Compensatory enlargement of human atherosclerotic coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Membrane interaction of calcium channel antagonists modulated by cholesterol. Implications for drug activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Influence of pHo on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Interactions of cholesterol with the membrane lipid matrix. A solid state NMR approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Cholesterol and the cell membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

The effect of cholesterol on the structure of phosphatidylcholine bilayers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Structural analysis of hydrated egg lecithin and cholesterol bilayers. I. X-ray diffraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Crystallization of free cholesterol in model macrophage foam cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Calcium antagonists and cardiovascular risk in diabetes. A review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Epidemiology of Hypertension in Diabetic Patients and Implications for Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Isradipine in prediabetic hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Calcium antagonists and cardiovascular risk in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

Calcium-channel blockers for hypertension--uncertainty continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900729-8

10.1016/S0021-9150(01)00729-8

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference